scorecardresearchThese two diagnostics stocks are down 40-60% this year but brokerages sees more downside

These two diagnostics stocks are down 40-60% this year but brokerages sees more downside

Updated: 16 Sep 2022, 10:35 AM IST
TL;DR.
Dr. Lal Pathlabs and Metropolis Healthcare: The listed diagnostic players are facing intense competition from the new entrants. Aggressive pricing and new bundled offering will lower margins and lower realization per patient for large incumbent chains.
The diagnostic industry is facing high competition, particularly in the high-margin routine test segment in metro cities, says Sayantan Maji, analyst at Credit Suisse.

The diagnostic industry is facing high competition, particularly in the high-margin routine test segment in metro cities, says Sayantan Maji, analyst at Credit Suisse.